Deelnemende volksgezondheidsinstanties hebben nu toegang tot SpeeDx-diagnostiek en bijbehorende diensten in het VK

SYDNEY & LONDEN–(BUSINESS WIRE)– SpeeDx Pty, Ltd., een ontwikkelaar van innovatieve moleculaire diagnostische oplossingen, is opgenomen in het nieuwe National Microbiology Framework van Public Health England (PHE) om diagnostische goederen en diensten in het VK te leveren.

Onder perceel 1 van het raamwerk hebben deelnemende volksgezondheidsinstanties toegang tot in-vitrodiagnostiek (IVD’s) en bijbehorende diensten van SpeeDx. Het aanbod omvat de onlangs gelanceerde CE-IVD PlexPCR® SARS-COV-2 – een moleculaire test met twee doelen om te helpen bij de diagnose van COVID-19. De niet-exclusieve overeenkomst stroomlijnt de toegang van laboratoria tot belangrijke leveranciers en zorgt voor eenvoudigere toegang tot SpeeDx-producten ter ondersteuning van het Britse plan om veerkracht op te bouwen in diagnostische toeleveringsketens.

SpeeDx Included in New PHE National Microbiology Framework

Participating public health authorities can now access SpeeDx diagnostics and associated services across the UK

SYDNEY & LONDON–(BUSINESS WIRE)– SpeeDx Pty, Ltd. a developer of innovative molecular diagnostic solutions- has been included in the new Public Health England (PHE) National Microbiology Framework to supply Diagnostic goods and services across the UK.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005397/en/

Under Lot 1 of the framework, participating public health authorities can access in-vitro diagnostics (IVDs) and associated services from SpeeDx. Offerings include the recently launched CE-IVD PlexPCR® SARS-COV-2– a dual-target molecular assay to aid in the diagnosis of COVID-19. (Graphic: Business Wire)

Under Lot 1 of the framework, participating public health authorities can access in-vitro diagnostics (IVDs) and associated services from SpeeDx. Offerings include the recently launched CE-IVD PlexPCR® SARS-COV-2– a dual-target molecular assay to aid in the diagnosis of COVID-19. The non-exclusive agreement streamlines laboratory access to key suppliers and allows for easier access to SpeeDx products to support the UK plan of building resilience in diagnostic supply chains.

“We are delighted to be included on the framework under Lot 1,” said SpeeDx Director of Sales, Warwick Need. “We look forward to working with PHE to bring our entire Respiratory and Sexual Health portfolio to the framework. Our suite of molecular diagnostics are designed to meet urgent unmet clinical needs in the respiratory infections, sexual health, and antibiotic resistance. We look forward to more opportunities of working together with PHE and participating laboratories so we can continue to make a positive impact on both the laboratory and overall patient management.”

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin, Texas and London, UK, with distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005397/en/

Contacts

Madeline O’Donoghue

+61 2 9209 4170

madelineo@speedx.com.au